Last reviewed · How we verify
NCT07305259: REACT
Researching Economical Adjuvants to Cancer Therapy
EARLY_PHASE1 trial testing Beta-glucan in Healthy Participants in 60 participants. Currently enrolling.
30 September 2029
Quick facts
| Lead sponsor | Florida State University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 60 |
| Start date | 12 November 2025 |
| Primary completion | 30 September 2029 |
| Estimated completion | 30 September 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Beta-glucan — full drug profile →
- Placebo
Conditions studied
- Healthy Participants — all drugs for Healthy Participants →
Sponsor
Florida State University
Who can join
Adults 18 to 45, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Does beta-glucan change the ability of immune cells to recognize cancer cells? 2. Does exercise change the type of immune cells in the blood? Researchers will compare beta-glucan to a placebo (a look-alike substance with no effect) to see if beta-glucan could improve immune function against cancer. Participants will: 1. Take beta-glucan or a placebo daily for 4 weeks. 2. Visit the laboratory for three exercise tests. 3. Provide blood samples so researchers can study immune system cells.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07305259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Beta-glucan
Trials testing the same drug.
- NCT05524688 — Beta-glucan and Fatigue in HSCT Survivors · Phase 1, PHASE2 · terminated
- NCT05074303 — Beta-glucan and Immune Response to Influenza Vaccine · Phase 2 · completed
- NCT04114513 — Dietary Fibers Effect on the Gut Microbiota Composition · NA · withdrawn
Other recruiting trials for Healthy Participants
Currently open trials in the same condition.
- NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
- NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
- NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
- NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
Other Florida State University trials
Trials by the same sponsor.
- NCT06127914 — Learning Early Infant Feeding Cues · NA · not yet recruiting
- NCT06015581 — Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida · NA · not yet recruiting
- NCT07467473 — Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression · NA · enrolling by invitation
- NCT07221448 — Sodium vs Potassium Education to Improve Vascular Health · NA · recruiting
- NCT07415941 — MBM and taVNS for Low Back Pain and Depressive Symptoms · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07305259 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Florida State University
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07305259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing